Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin

被引:2
|
作者
De Novelli, Fernando Jose
Przysiezny, Andre
Rosa, Evandro Luis
Liermann Garcia, Raquel Francine
Nobrega, Mario Junqueira
机构
[1] Hepatol Clin Sao Jose Reg Hosp, Sao Jose, SC, Brazil
[2] Sadalla Amin Ghanem Eye Hosp, Vitreoretinal Dept, Joinville, SC, Brazil
关键词
Antiviral agents/adverse effects; Hepatitis C; chronic/drug therapy; Interferon-alpha/adverse effects; Retinal diseases/chemically induced; Ribavirin/adverse effects; CHRONIC ACTIVE HEPATITIS; CHRONIC VIRAL-HEPATITIS; INDUCED RETINOPATHY; RETINAL COMPLICATIONS; VIRUS-INFECTION; ALPHA THERAPY; HYPERTENSION; ALFA;
D O I
10.5935/0004-2749.20140045
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To identify the effect of pegylated interferon alpha-2b and ribavirin treatment in the ocular fundus examination, visual acuity, and visual field. Methods: Prospective observational study was performed at the Hepatology Clinic of Sao Jose Regional Hospital and at the Vitreoretinal Department at the Sadalla Amin Ghanem Eye Hospital in patients with chronic hepatitis C before and during treatment with pegylated interferon alpha-2b together with ribavirin. Results: Six (37.5%) of 16 patients developed retinopathy during the treatment, two of which (12.5%) presented retinal hemorrhage, and four patients (6 eyes) presented cotton-wool spots (25%) that regressed during the treatment. One patient (6.25%) presented transient decrease in visual acuity during the treatment and recovered spontaneously without specific therapy. Conclusion: Recommended treatment methods for hepatitis C may cause transient retinopathy, commonly without any damage to visual function in most patients. Although ocular involvement is rare, follow-up with an ophthalmologist is recommended during the course of the hepatitis C medication.
引用
收藏
页码:178 / 181
页数:4
相关论文
共 50 条
  • [21] A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C
    Jacobson, IM
    Gonzalez, SA
    Ahmed, F
    Lebovics, E
    Min, AD
    Bodenheimer, HC
    Esposito, SP
    Brown, RS
    Bräu, N
    Klion, FM
    Tobias, H
    Bini, EJ
    Brodsky, N
    Cerulli, MA
    Aytaman, A
    Gardner, PW
    Geders, JM
    Spivack, JE
    Rahmin, MG
    Berman, DH
    Ehrlich, J
    Russo, MW
    Chait, M
    Rovner, D
    Edlin, BR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11): : 2453 - 2462
  • [22] Management of depression in patients treated with pegylated interferon and ribavirin for hepatitis C
    Jamil, K. M.
    Cheng, W.
    Tarquinio, L.
    Allet, L.
    Flexman, J.
    Kontorinis, N.
    GUT, 2007, 56 : A126 - A126
  • [23] Management of depression in patients treated with pegylated interferon and ribavirin for hepatitis C
    Jamil, K. M.
    Cheng, W.
    Tarqunio, L.
    Connelly, C.
    McInerney, M.
    Nazareth, S.
    Connelly, C.
    Flexman, J.
    Allet, L.
    Kontorinis, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A317 - A317
  • [24] Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C
    Poynard, T
    GUT, 2003, 52 (10) : 1532 - 1532
  • [25] The Safety of Pegylated Interferon α-2a and α-2b Combined with Ribavirin in Patients with Chronic Hepatitis C Based on the Japanese Interferon Database
    Sato, Izumi
    Kawasaki, Yohei
    Imai, Takumi
    Tanaka, Sachiko
    Yamada, Hiroshi
    Kawakami, Koji
    Masaki, Naohiko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 308 - 309
  • [26] Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon α2a or α2b
    Vispo, Eugenia
    Barreiro, Pablo
    Rodriguez-Novoa, Sonia
    Morello, Judit
    Lobarga, Pablo
    Martin-Carbonero, Luz
    Maida, Ivana
    Garcia-Gasco, Pilor
    Soriano, Vincent
    ANTIVIRAL THERAPY, 2008, 13 (04) : 511 - 517
  • [27] Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon α-2b and ribavirin
    Kawashima, Aiko
    Tsukamoto, Ikuyo
    Koyabu, Tomoko
    Murakami, Yasuko
    Kawakami, Takayo
    Kakibuchi, Naoko
    Takaguchi, Kouichi
    Kita, Keiji
    Okita, Misako
    LIPIDS, 2008, 43 (04) : 325 - 333
  • [28] IMPACT OF PEGYLATED INTERFERON α2B PLUS RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C PATIENTS WITH HISTORY OF HEPATOCELLULAR CARCINOMA
    Ogawa, E.
    Furusyo, N.
    Kajiwara, E.
    Takahashi, K.
    Nomura, H.
    Tanabe, Y.
    Satoh, T.
    Maruyama, T.
    Nakamuta, M.
    Kotoh, K.
    Azuma, K.
    Dohmen, K.
    Shimoda, S.
    Hayashi, J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S452 - S452
  • [29] Prevalence and Impact of Occult Hepatitis B Infection in Chronic Hepatitis C Patients Treated With Pegylated Interferon and Ribavirin
    Levast, Marion
    Larrat, Sylvie
    Thelu, Marie-Ange
    Nicod, Sandrine
    Plages, Agnes
    Cheveau, Alice
    Zarski, Jean-Pierre
    Seigneurin, Jean-Marie
    Morand, Patrice
    Leroy, Vincent
    JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (05) : 747 - 754
  • [30] Severe interstitial pneumonitis secondary to pegylated interferon α-2b and ribavirin treatment of hepatitis C infection
    Fuhrmann, V
    Kramer, L
    Bauer, E
    Laferl, H
    Tucek, G
    Dekan, G
    Schenk, P
    DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (11-12) : 1966 - 1970